Globus Medical's post-NuVasive integration has driven a remarkable margin transformation, with gross margin expanding from 59.9% in Q4 2024 to 69.4% in Q2 2026 and operating margin rising from 9.2% to 23.1% over the same period.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 27% in Q1 2026 but slowed to 5.9% in Q2 2026, while gross margin expanded to 69.4% and operating margin reached 23.1%, reflecting strong operational leverage.
Record Q4 and full year 2025 results, along with raised non-GAAP EPS guidance, indicate robust financial health.
Management reaffirmed 2026 revenue guidance of US$3.18 billion to US$3.22 billion, signaling confidence in future growth.
Operating in the Medical Devices sector, Globus Medical is well-positioned in a high-growth industry.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $1.23+2.5% vs $1.20 | $764M-3.6% vs $792M |
Q3 2026 Aug 6, 2026 | $1.34+21.8% vs $1.10 | $790M+0.9% vs $783M |
Q2 2026 May 7, 2026 | $1.12+21.7% vs $0.92 | $760M+2.6% vs $740M |
Q1 2026 Feb 24, 2026 | $1.28+20.8% vs $1.06 | $826M+3.1% vs $802M |
Globus Medical NYSE: GMED lowered its 2026 revenue forecast after third-quarter sales fell, citing continued declines at its Nevro business, delayed spine product launches and lower contributions from competitive sales recruiting.
Globus Medical cuts its 2026 revenue outlook amid spine launch delays and weak Nevro sales while shifting its focus to new products and growth opportunities in 2027.
Globus Medical, Inc. (GMED) Q3 2026 Earnings Call Transcript
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Benchmark GMED against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Globus Medical, Inc. (GMED)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $71.05 | $9.58B | 17.33 | 16.65% | 17.76% | 11.82% | — | |
| $325.87 | $124.93B | 34.60 | 11.16% | 13.78% | 15.61% | 1.03% | |
| $105.59 | $20.43B | 26.33 | 7.2% | 8.96% | 6.05% | 0.91% | |
| $7.44 | $1.14B | -13.48 | 24.95% | -10.35% | -547.17% | — | |
| $0.29 | $40.59M | -3.64 | 14.21% | -10.17% | -23.45% | — | |
| $101.80 | $130.7B | 25.01 | 8.43% | 13.93% | 10.51% | 2.78% |
Globus Medical, Inc. (GMED) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Globus Medical, Inc. (GMED) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 4, 2026·SEC
May 7, 2026·SEC
Get notified when GMED posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Globus Medical, Inc. (GMED) stock FAQ — growth, dividends, profitability & financials explained
Globus Medical, Inc. (GMED) reported $3.14B in revenue over the trailing twelve months. Revenue was $2.94B in fiscal year 2025. That is 920% more than the $288.2M of fiscal year 2010.
Globus Medical, Inc. (GMED) grew revenue by 13.4% over the trailing twelve months, compared with the twelve months before.
Yes. Globus Medical, Inc. (GMED) earned $557.7M in net income over the trailing twelve months (a 17.8% net margin).
Globus Medical, Inc. (GMED) had a return on equity (ROE) of 11.8% over the trailing twelve months. That is in line with the market's typical 10-15%.
Globus Medical, Inc. (GMED) generated $756.5M in free cash flow over the trailing twelve months.
